Today we're bringing you an insightful article published by AJMC that highlights Dr. Aimee Tharaldson's picks for two new key drugs for 2017. Her top picks are Ocrevus, the first drug approved to treat primary progression MS and Dupixent, a drug we featured earlier this week that will help patients with severe atopic dermatitis.
Hear Dr. Tharaldson talk about these new drugs by clicking the link to the full article HERE!
Performance Pharmacy Solutions (PPS) is a unique pharmacy benefit procurement platform developed by HORIZON Health Ventures to
efficiently and effectively place, manage and oversee our self-funded
client's pharmacy benefit management programs. The PPS platform provides
turnkey solutions with proven market-leading PBM partners that offer,
on average, 10-15% savings.
Ocrevus.
This is going to be the first drug approved to treat primary
progression MS. - See more at:
http://www.ajmc.com/conferences/amcp-2017/dr-aimee-tharaldson-highlights-two-key-drugs-for-2017#sthash.Vc34Z7Iv.dpuf
Ocrevus.
This is going to be the first drug approved to treat primary
progression MS. - See more at:
http://www.ajmc.com/conferences/amcp-2017/dr-aimee-tharaldson-highlights-two-key-drugs-for-2017#sthash.Vc34Z7Iv.dpufjj
Ocrevus.
This is going to be the first drug approved to treat primary
progression MS. - See more at:
http://www.ajmc.com/conferences/amcp-2017/dr-aimee-tharaldson-highlights-two-key-drugs-for-2017#sthash.Vc34Z7Iv.dpuf
No comments:
Post a Comment